Interleukin-6 and Soluble Interleukin-6 Receptor Levels as Markers of Disease Extent and Prognosis in Neuroblastoma
- 1 November 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (21), 7028-7034
- https://doi.org/10.1158/1078-0432.ccr-07-5017
Abstract
Purpose: To explore the relationships between interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) levels and disease extent and clinical outcome in childhood neuroblastoma. Experimental Design: Pretreatment peripheral blood (PB; n = 53) and bone marrow (n = 18) samples from patients with neuroblastoma were assayed by ELISA for IL-6 and sIL-6R. PB values were compared with healthy pediatric controls (n = 28). Results: PB IL-6 levels were significantly elevated in patients with high-risk disease compared with those with low and intermediate risk disease (23.9 versus 4.3 pg/mL; P < 0.001) and the normal control group (23.9 versus 3.3 pg/mL; P < 0.001). Similarly, bone marrow IL-6 levels were higher in high-risk patients when compared with low- and intermediate-risk patients (15 versus 0 pg/mL; P < 0.02). Other factors correlated with higher IL-6 levels were age of >18 months, bony metastases, and unfavorable histology. sIL-6R levels were not significantly correlated with disease stage. Patients with detectable PB IL-6 at diagnosis had significantly lower event-free survival rates (P < 0.008). sIL-6R levels 4 pg/mL were also associated with a significantly worse event-free survival (P = 0.016). Conclusion: Elevated PB IL-6 levels correlated with features of high-risk neuroblastoma and poor prognosis in this population. Decreased PB sIL-6R levels correlated with the presence of metastatic disease. Further study of these markers in children with neuroblastoma seems warranted.Keywords
This publication has 40 references indexed in Scilit:
- Significance of interleukin-6 (IL-6) in breast cancer (review)Breast Cancer Research and Treatment, 2006
- Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique andof probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donorsMediators of Inflammation, 2006
- The role of IL-6 and STAT3 in inflammation and cancerEuropean Journal Of Cancer, 2005
- The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480Clinical Cancer Research, 2005
- Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer CellsCancer Research, 2005
- Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different TechniquesClinical Cancer Research, 2004
- Cytokine serum levels in soft tissue sarcoma patients: Correlations with clinico‐pathological features and prognosisInternational Journal of Cancer, 2002
- Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective studyCytokines, Cellular & Molecular Therapy, 2002
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINESAnnual Review of Immunology, 1997